IL6 and acute lymphoblastic leukemia: These observations explain why the use of anti–IL-6 antibody therapy was not able of modifying the course of the disease, and underscore the limitations of the use of ex vivo functional studies involving leukemic pro-B cell in vitro expansion and bone marrow transplantation to identify how inflammatory signaling affects B-ALL development.